Skip to main content

#160866

Anti-PAX-FOXO1 [PaxF]

Cat. #160866

Anti-PAX-FOXO1 [PaxF]

Cat. #: 160866

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: The junction region of the PAX3-FOXO1 and the PAX7-FOXO1 fusion proteins

Class: Monoclonal

Application: ChIP ; IHC ; IF ; IP ; WB ; ChIP-seq

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: National Human Genome Research Institute

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-PAX-FOXO1 [PaxF]
  • Alternate name: PFM.2
  • Research fields: Cancer
  • Clone: PaxF
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Molecular weight: 105 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ChIP ; IHC ; IF ; IP ; WB ; ChIP-seq
  • Description: Alveolar Rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer and cases with fusion oncoproteins PAX7-FOXO1 and PAX3-FOXO1 have a poor prognosis. Determination of the fusion status is important for RMS diagnostics and therapies. This antibody is specific for the PAX3-FOXO1 and PAX7-FOXO1 and therefore is a valuable tool to study the oncogenesis of ARMS
  • Immunogen: KLH conjugated with peptide PF corresponding to the PAX3-FOXO1 translocation region aa 100-117 (TIGNGLSPQNSIRHNLSL) in Freund’s adjuvant
  • Isotype: IgG2b kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: Cell lysate from FP-RMS lines (e.g., RH-4, RH-28, RH-30, RMS-13)

Target Details

  • Target: The junction region of the PAX3-FOXO1 and the PAX7-FOXO1 fusion proteins
  • Molecular weight: 105 kDa

Applications

  • Application: ChIP ; IHC ; IF ; IP ; WB ; ChIP-seq

Handling

  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Azorsa et al. 2021. Mod Pathol. 34(4):748-757. PMID: 33299109.
  • Gryder et al. 2017. Cancer Discov. 7(8):884-899. PMID: 28446439.
  • Cao et al. 2010. Cancer Res. 70(16):6497-508. PMID: 20663909.
  • Khan et al. 1999. Proc Natl Acad Sci U S A. 96(23):13264-9. PMID: 10557309.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.